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1. Introduction 
Until 2005, T helper (CD4+) cells were proposed to be a binary system, consisting of TH1 and 
TH2 cells (Mosmann TR et al.,1986) , when a third T helper -cell subset, known as TH17 
(interleukin-17 (IL-17) expressing cells), was identified (Harrington LE et al., 2005, Park H et 
al., 2005). This was followed up by the another independent discovery in three different 
laboratories of the differentiation factors cytokines such as interleukin (IL)-6 and 
transforming growth factor beta (TGF-β), that simplified in vitro analysis of this T cell subset  
to a large extent (Veldhoen M et al., 2006, Bettelli E et al., 2006, Mangan et al.,  2006). The 
discovery of these unique TH17 cells has opened up exciting new avenues for research into 
the etiology and therapeutics of a broad spectrum of human diseases and data on the 
biology of these cells have emerged at an astounding pace in just 5 years. The reason for 
these cells to receive considerable attention in these recent years is their emerging 
involvement as principal mediators of pathogenesis in several autoimmune and chronic 
inflammatory disorders. Many reviews of the field have already highlighted the important 
role of TH17 cells in the diverse group of human autoimmune and inflammatory diseases 
(Tesmer et al., 2008, Sallusto and Lanzavecchia 2009, Torrado and Cooper 2010, Kimura and 
Kishimoto 2011, Cosmi et al., 2011).  
With regards to cancer, the involvement of TH17 cells in tumour immunology has raised 
their status as a target for cancer therapy. However based on the reported evidence on the 
potential anti-tumourigenic and pro-tumourigenic activities of TH17 cells, their role as 
friends or foes, respectively is still under debate; could be because of a few studies have 
focused on primary TH17 cells in the human tumour microenvironment (Wilke et al., 2011). 
The link between cancer development and inflammation is now widely accepted and cancer 
patients have local and systemic changes in inflammatory parameters (Chechlinska, et al., 
2010). Tumours frequently display the characteristics of chronically inflamed tissue, 
including immune cell infiltration and an activated stroma (Kanwar et al., 2008, Mantovani 
et al., 2008). Indeed inflammation has been proposed as the seventh trait of cancer by 
supplementing Hanahan and Weinberg’s model that identifies six hallmarks of cancer 
(Mantovani 2009). This chapter focuses on the role of TH17 cells in cancer by understanding 
its links with chronic inflammation.  
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2. Association of cancer with inflammation 
Inflammation is the first line of defence against various extracellular stimuli (microbes, 
trauma, chemicals, heat or any other phenomenon) and can be acute or chronic. Acute or 
physiological inflammation is when body cells respond to external stimuli for short periods 
of time. Normal inflammation, for example, inflammation associated with acute infections, 
injury, wound healing is usually self-limiting; however, dysregulation of any of the 
involved factors leads to abnormalities. If the stimulus sustains for longer time, it results in a 
pathological state known as chronic or pathological inflammation as seen in autoimmune 
and chronic inflammatory  diseases such as atherosclerosis, multiple sclerosis, rheumatoid 
arthritis, allergic inflammation of the lung leading to asthma (Kanwar et al., 2001a, Kanwar 
2005, Kanwar et al., 2008, Kanwar et al., 2009, Barreiro et al., 2010). Chronic inflammation is 
also the case during tumour progression in cancer. The patients with chronic inflammatory 
conditions have a greatly increased risk of cancer in the affected organs. Also chronic 
inflammation resulting from viral or bacterial infections can often lead to or hasten the 
development of malignancy (Coussens and Werb 2002, Kanwar et al., 2011). Table 1 
summarizes the chronic inflammatory conditions associated with cancer.  
 
 
Inflammatory Condition  Associated Cancer(s)  
AIDS  Non-Hodgkin’s lymphoma, squamous cellcarcinomas, Kaposi’s sarcoma 
Asbestosis, silicosis  Mesothelioma, lung carcinoma  
Barrett’s oesophagus  Oesophageal carcinoma  
Bronchitis  Lung carcinoma  
Chronic cholecystitis  Gall bladder cancer  
Chronic pancreatitis, hereditary pancreatitis  Pancreatic carcinoma  
Coeliac disease Lymphoma 
Gingivitis Oral squamous cell carcinoma  
Helicobacter pylori infection Gastric cancer 
Hepatitis B or C Hepatocellular carcinoma  
Inflammatory bowel disease, Crohn’s disease, 
chronic ulcerative colitis  Colorectal carcinoma  
Lichen sclerosus  Vulvar squamous cell carcinoma  
Mononucleosis  B-cell non-Hodgkin’s lymphoma, Burkitts lymphoma,  
Obesity related inflammation Liver cancer 
Opisthorchis, Cholangitis  Cholangiosarcoma, colon carcinoma  
Osteomyelitis  Sarcoma 
Pelvic inflammatory disease, chronic cervicitis  Ovarian carcinoma, cervical/anal carcinoma  
Prostate inflammatory atrophy Prostate cancer 
Rheumatoid arthritis Lymphoma 
Shistosomiasis, bladder inflammation  Bladder carcinoma  
Sialadenitis  Salivary gland carcinoma  
Sjögren syndrome, Hashimoto’s thyroiditis  MALT lymphoma  
 Skin inflammation  Melanoma  
Modified from Coussens and Werb, 2002,  Conro y et al., 2010 
Table 1. Chronic inflammatory conditions and infections associated with cancer. 
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When the control of cell proliferation, growth and cell death (apoptosis) is lost, we obtain a 
clone of cells known as benign tumour. By growing its own blood supply (angiogenesis), the 
tumour feeds itself, grows indefinitely and spreads (metastasizes) in the body thereby leads 
to malignant cancer. Tumour cells are known to produce various pro inflammatory 
cytokines such as IL-1β, IL-6, IL-23 and tumour necrosis factor (TNF)-αand chemokines that 
attract inflammatory leukocytes which include neutrophils, dendritic cells, macrophages, 
eosinophils, mast cells and lymphocytes (Coussens and Werb 2002, Kanwar et al., 2008,). 
These cells further produce growth factors, various cytokines, chemokines, cytotoxic 
mediators like reactive oxygen species, matrix metalloproteinases (MMPs), membrane-
perforating agents and soluble mediators of cell killing such as TNF-α, interleukins and 
interferons (Wahl et al., 1998,  Kuper et al., 2000, Coussens and Werb 2002,  Kanwar et al., 
2008). The recruitment of dendritic cells capture antigen and stimulate anti-tumour 
immunity by T lymphocyte activation which kill cancer cells via cell mediated cytotoxicity 
(Kanwar et al., 1999). According to the immune surveillance theory, tumours arise only if 
cancer cells are able to escape immune surveillance, yet sometimes a robust immune 
response might result in a favourable effect that might be due to CD8+ cytotoxic T cells 
which have the capacity to kill tumour cells (Kanwar et al., 2001b) CD4+ T cell responses are 
also important as they help recruiting CD8+ cytotoxic T cell and generate an inflammatory 
response that chains the function of CTLs activity (Kanwar et al., 2003). The growth factors 
asnd  cytokines released by inflammatory cells can also have pro-tumour actions. They can 
lead to proliferation, survival and migration of the tumour by promoting angiogenesis and 
lymphanogenesis, remodelling extracellular matrix to facilitate invasion, coating tumour 
cells to make available receptors for spreading cells via lymphatics and capillaries, and 
evading host mechanisms (Coussens and Werb 2002, Rigo et al., 2010). In this context 
tumour-associated macrophages (TAMs) have a significant role. After migration the 
monocytes, recruited largely by monocyte chemotactic protein (MCP) chemokine become 
the significant component of inflammatory infiltrates as TAMs in neoplastic tissues, and has 
a dual role in neoplasms. TAMs may kill neoplastic cells following activation by IL-2, 
interferon and IL-12 or potentiate neoplastic progression through the production of a 
number of potent angiogenic and lymphangiogenic growth factors, cytokines and proteases, 
all of which are mediators for tumour growth (Brigati et al., 2002, Tsung et al., 2002). Further 
TAMs and tumour cells also produce IL-10, which effectively blunts the anti-tumour 
response by cytotoxic T cells, and prevent maturation of anti-tumour dendritic cells in situ 
leading to immunosuppression and immune evasion (Coffelt et al., 2009). Increasing 
evidences have suggested that many types of cancer are closely associated with 
inflammation (Table 1). Thus, inflammation is a process used by immune cells to eliminate 
cancer and by cancer cells to promote tumour progression and metastasis. 
3. CD4+ T cell subsets as essential regulators of immune responses and 
inflammatory diseases 
Immune system consists of innate and adaptive immunity. Adaptive immunity is mediated 
by T and B cells. T helper cells/CD4+ cells are the key actors in establishing an immune 
response. Naive CD4+ T cells differentiate into different types of effector cells depending 
upon the combination of cytokines in milieu, antigen and the antigen presenting cell (APC). 
There are four types known so far (Figure 1) and include TH1, TH2, T- regulatory (Treg) and 
TH17. TH1 cells, induced by IL-12, express TH1 specific Transcription factors (T-bet) and 
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produce IFN-γ as their signature cytokine and evoke cell-mediated immunity and 
phagocyte-dependent inflammation. Vigorous pro-inflammatory activities of TH1 cells has 
been seen to cause tissue damage and elicit unwanted TH1-dominated responses in the 
pathogenesis of organ-specific  autoimmune/inflammatory disorders, Crohn's disease, 
sarcoidosis, acute kidney allograft rejection, and some unexplained recurrent abortions 
(Romagnani, 2000).  
 
Fig. 1. CD4+ T- Cell differentiation: Naive CD4+ T cells differentiate into different effector 
cells under the influence of the pool of cytokines present in the surroundings. There are four 
known types of effector TH cells which have different functions based on the expression of 
unique transcription factors and characteristic cytokines. 
TH2 cells are induced by IL-4, express GATA 3 and produce IL-4, IL-5, IL-9, IL-10 and IL-13. 
These are associated with the humoral immunity and resistance against extracellular forms 
of pathogens. T-regulatory (Treg) cells, characterized by expression of FoxP3 
(forkhead/winged helix transcription factor), produce TGF-β (transforming growth factor-
β1). These distinct regulatory T cell subsets  suppress adaptive T cell responses, have anti-
inflammatory role and are involved in maintaining tolerance to self components (prevent 
autoimmunity).  
TH17 cells, a newly defined lineage of CD4+ cells,  are not only distinct from other TH cells in 
their gene expression and regulation, but also in terms of their biological function (Dong 
2008) TH17 cells are characterized  in particular through the production of IL-17 and IL-17F, 
and have functions in autoimmune diseases, inflammation and host defence against 
infectious pathogens. Recently accumulating evidence suggests that TH cells possess 
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functional ‘plasticity’  (Bettelli et al., 2006, Yang et al., 2008a, Crome et al., 2010a) i.e. they can 
be converted into other types of TH cells under in vitro as well as in vivo conditions. This 
property seems to be certainly beneficial to mount different and varied responses for 
combating immunological insults given at short notices.  
TH17 cells: a new lineage of effector TH cells Discovery: The presence of TH17 cells as a 
specific lineage was recognized when it was demonstrated that lipopeptides from the 
spirochete Borrelia burgdorferi triggered the increased levels of IL-17A mRNA in T cells to 
produce IL-17 (member of IL-17 family composed of 6 cytokines, IL-17A-F), TNF-α and GM-
CSF while these cells were negative for IFN-γ or IL-4, revealing a novel cytokine phenotype 
distinct from TH1 or TH2. (Infante-Duarte et al., 2002). This was the first report to establish 
the link between bacterial infection and a new effector T cell phenotype later to become 
TH17 while foretelling the description of a factor later identified as critical to TH17 
development: IL-6 (Weaver et al., 2007) . Further hint came when, Aggarwal et al. 2003, who 
demonstrated that IL-23 stimulates murine CD4+ T cells to secrete IL-17 following 
stimulation of the T- cell receptor (TCR). These crucial findings that IL-23 but not IL-12, 
stimulated memory, but not naive, CD4 T cells to produce IL-17A and IL-17F, were 
consistent with a unique effector CD4 T cell population similar to that previously reported 
by Infante-Duarte and colleagues in 2002. Then the findings that IL-17 secreting CD4+ T 
cells arise in the absence of TH1 and TH2 induced transcription factors and cytokines  
solidified the lineage separation between TH1/TH2 and TH 17 cells (Harrington et al., 2005; 
Park et al., 2005). 
Differentiation and transcriptional regulation: Although early studies by Aggarwal and 
colleagues in 2003 implicated IL-23 in driving TH17 expression and generation , it was later 
on demonstrated that IL-23 receptor (IL-23R) is not expressed on naïve T cells. Instead, IL-
23, as well as TNF-α, acts as survival signals for TH17 cells. It is apparent now as reviewed 
recently (Weaver et al., 2007, Torchinsky and Blander 2010, Kimura and Kishimoto 2011) that 
IL-23 is important only for TH17 cells’ expansion, survival and pathogenicity. The key 
cytokines required for TH17 differentiation, surprisingly, are a combination of pro-
inflammatory and anti-inflammatory cytokines; i.e, IL-6 and TGF-β respectively (Veldhoen 
M et al., 2006, Mangan et al., 2006, Betteli et al., 2006). The studies by Betteli and colleagues 
identified TGF-β as a critical factor for TH17 commitment while IL-6 acted to deviate TGF-β-
driven development of Foxp3-expressing Tregs toward TH17 (Betteli et al., 2006).  
Further attempts were made to delineate the precise signalling mechanisms through which 
IL-6 and TGF-β cooperate to induce TH17 differentiation. Studies have shown that the key 
transcription factors in determining the differentiation of the TH17 lineage are retinoid-
related orphan receptor γt (RORγt) and RORα which can be induced by the combination of 
IL-6 and TGF-β (Ivanov et al., 2006, Yang et al., 2008b). RORt was shown to be specifically 
expressed by mouse and human TH17 cells (Ivanov et al., 2006, Wilson et al., 2007). Further a 
central role for IL-6-induced STAT3 activation was made evident. Although IL-6 activates 
both STAT3 and STAT1, it has been demonstrated that STAT3 activation is maintained 
while STAT1 activation is suppressed in TH17 cells (Kimura et al., 2007). Interferon 
regulatory factor (IRF) 4 and T-bet are other players in the scene of transcriptional 
regulation, which act as positive and negative regulators of TH17commitment, respectively 
(Brüstle et al., 2007, Rangachari et al., 2006). Further Aryl hydrocarbon receptor (Ahr) was 
shown to be induced under TH17-polarizing conditions such as in the presence of TGF-β 
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plus IL-6, and promotes TH17 cell development through inhibiting STAT1 and STAT5 
activation. More recently, an AP-1 transcription factor, BATF was shown to also play a role 
in TH17 differentiation. BATF-/- mice had a defect specifically in differentiation of TH17 
cells, and were resistant to autoimmune encephalomyelitis (Schraml et al., 2009). IL-1 
(Chung et al., 2009) and IL-21 (Korn et al., 2007) have also been shown to be required for 
their differentiation. And certain studies have shown that IL-10 released by Treg cells and 
IL-2 inhibit TH17 cell development (Weaver et al., 2007). - Apart from IL-17 as its major 
cytokine, TH17 cells also release IL-21 and IL-22 (Wei et al., 2007, Dong 2008). As IL-21 is 
required for TH17 cells’ differentiation as well as is produced by them, it may be acting as a 
positive feedback loop to amplify the production of these cells (Torchinsky and Blander 
2010). TH17 cells also express CCR6, CXCR4, CD49 integrins and CD161 (Kryczek, et al., 
2009). Crome et al., 2010b established a novel method to isolate in vivo differentiated TH17 
cells from peripheral blood by sorting CD161+CCR4+CCR6+CXCR3-CD4+T cells. These 
authors  also suggested low expression of granzyme A and B as another distinguishing 
feature of TH17 cells. TH17 cells also express IL-23R at high levels. There exists also a 
negative regulatory system for TH17 cell differentiation and IL-27 was shown to important 
role in curbing TH17 responses by limiting development of TH17 effectors (Batten et al.,2006, 
Stumhofer et al., 2006). Thus, various cytokines and transcription factors can either enhance 
or inhibit TH17 differentiation (Figure 2). Very recently, Martinez et al. in 2010 suggested that 
Smad2 positively regulates the generation of TH17 cells in vivo and in vitro (Figure 3). 
 
Fig. 2. Activators and inhibitors of TH17 differentiation: The figure below shows the different 
activators and inhibitors which promote or inhibit the differentiation of TH17 cells. 
Cytokine production: The TH17 lineage was originally defined by the production of hallmark 
cytokines interleukin-17 (also known as IL-17A) and IL-17F, members of IL-17 family 
(Aggarwal et al., in 2003) as homodimers or heterdimers (Liang et al., 2007). Later on studies 
have shown that TH17cells are also characterized by the production of IL-10 family cytokine, 
IL-22 (Liang et al., 2006). IL-21, besides acting in concert with TGF-β to promote TH17 
differentiation, is also produced by TH17 cells ( Korn et al. ,2007). TH17 cells are also known 
to produce certain cytokines that are expressed by other T helper cell lineages, including 
TNF-α and lymphotoxin-β, and the TH17 subset can be characterized by expression of 
chemokine receptor CCR6 and the  CCR6 ligand, CCL20 (Hirota et al., 2007, Torchinsky and 
Blander 2010). A subset of TH17 cells is reported to co-expresses IFN- in humans where as 
many as half of all the IL-17+ cells also express IFN-. It is not yet clear if these cells 
represent a stable phenotype or a transitional phase, undergoing a switch from TH17 to TH17 
or vice versa (reviewed by Tesmer et al., 2008) (Figure 3).  
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Fig. 3. TH17 differentiation and activation of immune cells for immune responses, 
inflammation, anti-cancer activity and hematopoiesis. 
Biological activities/functions: The important roles of IL-17 in host defence against many 
extracellular and intracellular pathogens have already been established (reviewed by 
Torchinsky and Blander 2010). IL-17A, F released by TH17 cells, is involved in the 
recruitment, activation and migration of neutrophils which help the body to fight against 
infection with various bacterial and fungal species (Yang et al., 2008c). Non-immune cells are 
major targets for the effector functions of TH17 cells. Specifically, cytokines produced by 
TH17 cells act on cells such as fibroblasts and keratinocytes (Chrome et al., 2010) and thereby 
contribute to immunity in barrier tissues such as the skin and gut. TH17 cells have also been 
involved with tissue repair functions through their production of the cytokine IL-22 along 
with IL-10 (Dong C 2008). Further the anti-infective and anti-inflammatory roles of IL-22 are 
associated with its functions in maintaining the integrity of epithelial barriers (Torchinsky 
and Blander 2010). More interestingly, it was shown that TGF-β and IL-6 from antigen 
presenting dendritic cells, that recognized apoptotic cells carrying TLR ligands, were able to 
drive differentiation of naı¨ve CD4+ T cells to the TH17 lineage (Torchinsky et al., 2009). Thus 
TH17 cells may be uniquely suited to serve in host response against pathogens causing 
significant apoptosis and tissue damage (Figure 3).  
There are effector molecules as discussed above (cytokines, chemokines and integrin α3 ) 
associated with TH 17 cells that act as pro-inflammatory mediators of inflammation and 
upregulate the expression of adhesion molecules thereby mediating the migration of 
circulating mixed leukocytes, such as monocytes, neutrophils, T cells and natural killer (NK) 
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cells. The infiltrated leukocytes further augment the ongoing inflammation, indirectly by 
secreting an elaborated number of chemokines and cytokines, including IL-1, IL-6, TNF-α, 
monocyte chemoattractant protein-1(MCP-1), keratinocyte-derived chemokine (KC), IFN-γ, 
IL-17, and IL-23 (Coussens and Werb 2002,  Kryczek et al, 2009a, Barreiro et al., 2010),. When 
these inflammatory signals are altered or misprocessed, the inflammation can become 
chronic, causing extensive tissue damage. To combat chronic inflammation in autoimmune 
diseases, novel therapeutic strategies targeting TH17 cells and their effector molecules  thus 
represent opportunities for therapeutic intervention. 
4. Association of TH17 cells with chronic inflammation 
Earlier, TH1 phenotype was associated with inflammation and autoimmunity and now the 
TH17 subset has also been described as pro-inflammatory to play a role in autoimunity and 
chronic inflammation. The findings that IFN- and IFN- receptor-deficient mice and mice 
lacking IL-12p35 and other molecules involved in TH1 differentiation were not protected 
from experimental autoimmune encephalomyelitis (EAE), but rather developed more severe 
disease have challenged the concept that autoimmunity is a TH1 driven disease process 
(Gran B et al., 2002, Torchinsky and Blander 2010). The suggestion about another subset of T 
cells, distinct from the TH1 lineage that might be required for the induction of EAE and other 
organ-specific autoimmune diseases has recently established role and importance of TH17 
cells in the pathogenesis of organ-specific autoimmune inflammation based on animal 
studies and clinical findings. The topic on the broad implications of TH17 cells in the 
pathogenesis of number of immune-mediated diseases such as psoriasis, rheumatoid 
arthritis, multiple sclerosis, inflammatory bowel disease, and asthma is beyond the scope of 
this chapter, but readers are referred to excellent recent reviews (Tesmer et al., 2008, Dong C 
2008,  Torchinsky and Blander 2010, Cosmi et al., 2011) (Figure 1).  
Inflammation and pathogenesis induced by TH17 cells is a result of the pro-inflammatory 
cytokines, chemokines and chemokine receptors these cells produce and express, 
respectively. Recently, TH17 polarized cells have been shown to be associated with cancers. 
Cancer and inflammation are now considered to be inextricably linked. Inflammatory 
mediators and cellular effectors are important constituents of the local environment of 
tumours. Many cancers arise from the sites of infection, chronic irritation and inflammation 
as shown in Table 1, the inflammatory conditions are present before a malignant change 
occurs. To understand the kinetics and targets of inflammation in a discussion of TH17 cells 
and cancer, the relationship between TH1-derived IFN, TH17 cells and antigen-presenting 
cells (APCs) in humans was recently studied (Kryczek et al., 2008a). These authors 
demonstrated in a cutting edge study that IFN could rapidly induce elevated B7-H1 
expression on APCs and stimulate their production of IL-1 and IL-23. B7-H1 signaling 
resulted in abrogation of the TH1-polarizing capacity of APC, whereas IL-1 and IL-23 
directed them toward a memory TH17-expanding phenotype. These findings thus suggest 
that in the course of inflammation, that the acute TH1-mediated response is attenuated by 
IFN-induced B7-H1 on APCs and is subsequently evolved toward TH17-mediated chronic 
inflammation by APC derived IL-1 and IL-23. This study in addition to challenging the 
dogma that IFN suppresses TH17 and enhances TH1 development, also strengthens the 
notion that TH17 kinetics depends strongly on the context of the ongoing immune reactions 
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and the constituents of the cytokine milieu, both of which are influenced by disease 
progression (Figure 3). 
5. TH 17 cells in cancer 
Various studies have been carried out in the recent years  with rapid progress on different 
cancer types to investigate  the association of cancer and TH17 cells. It has been seen that, 
TH17 cells, might either promote tumour growth or regulate antitumour responses. This 
may be due to the irregular conflicting data based on the studies in humans versus those in 
mice and contradictory data from experiments in immunocompetent versus 
immunodeficient mice (Wilke et al., 2011). There is, however, a strikingly high frequency of 
tumour-infiltrating TH17 cells in patients with diverse cancer types. These cells when 
examined in cancer patients, the findings reveal that  human tumour-associated TH17 cells 
express minimal levels of human leukocyte antigen (HLA)-DR, CD25 and granzyme B, 
suggesting that they are not a ‘conventional’ effector cell population (Wilke et al., 2011).  On 
examining the associated mechanisms and clinical significance of TH17 cells in 201 ovarian 
cancer patients, it was found that TH17 exhibited a polyfunctional effector T-cell phenotype, 
were positively associated with effector cells, and were negatively associated with tumour-
infiltrating Treg cells (Kryczek et al., 2009a). The study authors further reveal that for 
homing molecules, tumour-associated TH17 highly express  chemokine receptors CXCR4 
and CCR6, c-type lectin receptor CD161 and the CD49 integrin isoforms c, d and e, while 
CCR2, CCR5 and CCR7 are not present on these cells (Figure 3).  
Several biological activities of TH17 cells are directly or indirectly linked to human tumour 
pathogenesis. Tumour-associated TH17 cells have the ability to influence the tumour 
immune response through the action of their cytokines products in cancer patients which 
reportedly include high levels of pro inflammatory granulocyte-macrophage colony 
stimulating factor (GM-CSF), TNF-α, IL-2 and IFN, but negligible levels of anti-
inflammatory IL-10 . This phenotype was observed in six types of human cancers which 
include ovarian, colon, liver, skin, pancreatic and renal (Kryczek et al., 2009a). 50% of TH17 
cells, in patients with hepatocellular carcinoma (HCC) produced IFN-IFNγ, a typical TH1-
type cytokine (Zhang et al., 2009, Kryczek et al., 2009, Wilke et al., 2011). Further, on in vitro 
expansion, the TH17cells from tumour-infiltrating lymphocyte populations in melanoma, 
breast and colon cancers secrete elevated amounts of IL-8 and TNF-α, but no IL-2 (Su et al., 
2010). Since this profile has been seen previously in TH17 cells isolated from healthy donors 
(Liu and Rohowsky-Kochan 2008) and patients with autoimmune diseases (Kryczek et al., 
2008b), it may indicate a possible difference in the phenotypes of freshly isolated TH17cells 
and those expanded or induced in vitro from tumour-associated populations (Figure 3). 
Earlier information reviewed from both experimental animal systems and human cancer 
patients suggested that IL-17 and IL-23 are generally favourable to the growth of tumours 
thus overshadowing their roles in the generation of T-cell anti-tumour immunity (Tesmer et 
al., 2008). 
Still the role of IL-17 producing TH17 cells in cancer is elusive as different immunopathological 
implications of these cells have been observed in different malignancies. Analysis of tumour-
derived naive and memory CD4+ T cells revealed that IL-17 producing T cells are in memory 
phase as they are positive for CD45RO, but negative for CD45RA, CD62L, and CCR7 
(Miyahara et al., 2008). These authors also indicated that tumour cells may secrete key 
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cytokines required for the expansion of TH17 cells. Further Su et al., 2010 demonstrated 
elevated CD4+ TH17 cell populations in the tumour-infiltrating lymphocytes (TILs) and 
suggested development of tumour-infiltrating TH17 cells may be a general feature in cancer 
patients, when they extended their studies from ovarian cancers to melanoma, breast and 
colon cancers. Their study further demonstrated that tumour cells and tumour-derived 
fibroblasts, mediate the recruitment of TH17 cells by secreting chemokines RANTES (regulated 
upon activation, normal T cell expressed and secreted) and MCP-1 in the tumour 
microenvironment. The tumour microenvironments produce a pro-inflammatory cytokine 
milieu and provide cell–cell contact engagement that facilitates the generation and expansion 
of TH17 cells. They also showed that inflammatory TLR and nucleotide oligomerization 
binding domain (Nod2) 2 signalling promote the attraction and generation of TH17 cells and 
that this was induced by tumour cells and tumour-derived fibroblasts.  
6. Dynamic interaction between Treg and TH17 cells  
Levels of both Treg and TH17 cells increase synchronically following tumour development 
and are inversely associated. TGF-β promotes Treg development and both TGF-β plus IL-6 
are required for TH17 differentiation (Veldhoen M et al., 2006, Mangan et al., 2006, Betteli et 
al., 2006). Although, both the cytokines needed for TH17 cell development have been seen to 
be present in high levels in tumours (Zhou 2005), yet the levels of Treg cells and other T 
subsets are more than TH17 cells in both mouse and human tumours (Kryczek et al., 2007). 
So there must be something that prevents differentiation of TH17 cells. An interesting study 
by Kryczek and colleagues in 2009 from ovarian cancer patients, raised concerns on the roles 
of IL-6 an TGF-β, where it has been reported that inhibition of IL‑1β, but not IL‑6 or TGF-β, 
decreased TH17 cell induction by myeloid APCs isolated from patients, and the levels of 
IL‑17 and numbers of TH17 cells did not correlate with the levels of IL‑6 and TGF-β in these 
patients’ samples. These observations hinted a crucial role of only IL-1β, but not of IL-6 or 
TGF-β, for TH17 cell development in the ovarian cancer microenvironment. Similar support 
for a crucial role of IL-1β in promoting TH17 cell development has been reported in mouse 
studies (Chung et al., 2009, Gullen et al., 2010). 
According to few studies, IL-10 released by Treg cells negatively regulates differentiation of 
TH17 cells and IL-2, a growth factor for most T cells promote FoxP3 expression in TH17 cells 
and inhibit cellular differentiation to TH17 cells (Wilson et al., 2007). Retinoic acid has been 
found to enhance TGF-β signalling and decrease IL-6 signalling, thus, it might also be 
affecting the balance between TH17 and Treg cells. Apart from this, it has also been seen that 
mouse peripheral mature Treg can be converted to TH17 cells favoured by inflammation and 
IL-6 (‘plasticity’) (Yang et al., 2008a). The role of TGF-β in the differentiation of both induced 
Treg cells as well as TH17 cells, along with the documented interactions between RORα and 
FoxP3 that influence the two subsets, suggest a system that balances inflammation with 
tolerance (Figure 3). 
7. Evidences for the negative and positive roles of TH17 in anti-tumour 
Immunity 
Though reports have addressed the presence of TH17 cells in experimental and human 
tumours but they lack regarding the clear indication about either a pro-tumoural or anti-
 
TH17 Cells in Cancer Related Inflammation 
 
53 
tumoural activity of these cells (Bronte 2008).There are various biological functions  of TH17 
cells and their effector molecules as mentioned earlier in the chapter that could be on the 
basis of experimental and clinical data, suggest TH17 cells might either be positively or 
negatively co-related with cancer. 
Negative role of TH17 cells in anti-cancer 
IL-17 produced by TH17 cells is an angiogenic factor (Numasaki et al., 2003) which stimulates 
the migration and cord formation of vascular endothelial cells in vitro and elicits vessel 
formation in vivo which in turn promotes tumour growth and metastasis through de novo 
carcinogenesis and neovascularisation via STAT3 signalling. Another cytokine, IL-23 
required for TH17 activity has been identified as a cancer-associated cytokine because it 
promotes tumour incidence and growth (Langowski et al., 2006). It has been seen that TH17 
cells produce negligible levels of HLA- DR, CD 25, granzyme B, PD1 and FoxP3, all of which 
are involved in effector functions suggesting that they do not contribute to immune 
suppression in the tumour environment. Thus, as TH17 cells produce pro-inflammatory 
cytokines and have been found to accumulate in tumour microenvironment and as 
inflammation is linked to cancer development and progression, it is reasonable to predict a 
positive relation between these cells and cancer progression. Also, the data from 
experiments on ovarian cancer suggest that TH17 cells through TNF-α are  involved in the 
development or progression of cancer in mice and humans(Charles et al., 2009).  
Further TH17 cells might increase their own frequency in the tumour by both direct and 
indirect mechanisms (Zou and Restifo 2010). The induction of TH17 cells in the human 
tumour microenvironment through IL-1β production by the myeloid APCs may in turn 
promote dendritic cell trafficking into tumour-draining lymph nodes and the tumour 
environment by producing CCL20 (Kryczek et al., 2009a). Further as CCR6+ TH17 cells are 
known to efficiently migrate towards CCL20 (Kryczek et al., 2008b, Kryczek et al., 2009a), 
and CCL20 can then lead to the recruitment of dendritic cells to the tumour-draining lymph 
nodes and tumour itself in a CCR6-dependent manner (Martin-Orozco et al., 2009). 
Compared with corresponding non-tumour regions, the levels of TH17 cells were found to 
be significantly increased in tumours of HCC patients. Most of these intratumoural TH17 
cells exhibited an effector memory phenotype with increased expression of CCR4 and CCR6. 
Furthermore, the intratumoural cell density of TH17 correlated with poor survival in HCC 
patients (Zhang et al., 2009). A study from Kuang and colleagues in 2010, has demonstrated 
predominantly enriched levels of IL-17-producing cells in peritumoural stroma of murine 
HCC tissues, where their levels correlated with monocyte/macrophage density. The level of 
murine hepatoma-infiltrating CD4+ IL- 17+ cells as well as the tumour growth was reduced 
significantly when monocyte/macrophage inflammation in liver was inhibited via 
treatment with a Kupffer cell toxicant (gadolinium chloride).  
Similar to humans, healthy mice has limited populations of TH17 cells but these cells 
expanded in the blood, bone marrow and spleens but not in the tumour draining lymph 
nodes and largest populations were seen in tumour itself of mice with the aggressive B16 
melanoma, fibrosarcoma and advanced head and neck cancers, The number of CD4+IL-17+ 
T cells gradually increased in the tumour microenvironment during tumour development 
but interestingly, the number of these cells remained limited during tumour development in 
the tumour draining lymph nodes, including advanced tumour stages. (Kryczek et al., 
2007).On the other hand in nasopharyngeal carcinoma, data from human samples 
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demonstrated no correlation of TH17 cells with patient clinicopathological characteristics or 
survival outcomes (Zhang et al., 2010). Studies with patient samples from lung 
adenocarcinoma or squamous cell carcinoma revealed that malignant pleural effusion from 
these patients was chemotactic for TH17 cells, and this activity was partially abrogated by 
CCL20 and/or CCL22 blockade (Ye et al., 2010). Interestingly, higher infiltration of TH17 
cells in malignant pleural effusion predicted improved patient survival.  
Positive role of TH17 cells in anti-tumour immunity 
Both human and mouse tumours study data suggest several lines of evidence about the 
protective role of TH17 cells with the induction of protective anti-tumour immune 
response.TH17 cells have been seen to positively co-relate with effector immune cells like 
IFNγ+ effector T cells, cytotoxic CD8+ T cells and natural killer (NK) cells in the tumour 
microenvironment which might be to produce an anti- tumour response against cancer cells 
to kill them by promoting  cell mediated cytotoxicity (Kryczek et al., 2009a). Various 
experimental studies have shown that IL-17 overexpression or exogenous TH17 cell 
induction lead to decreased tumour growth, for example; Muranski and colleagues in 2008, 
through a  first functional study showed that TH17-polarized CD4+ T cells (following 
treatment with TGF-β and IL-6), induced potent tumour eradication of large established 
melanoma in mice. The study provides a support for a clinical trial involving the adoptive 
transfer of TH17-polarized, tumour-specific CD4+ T cells to patients with cancer. A year 
later, another interesting functional study, revealed  for the first time that TH17-polarized 
CD8+ T cells induce potent tumour eradication in mice,  and provided again support for a 
clinical trial involving the adoptive transfer of TH17-polarized, tumour-specific CD8+ T cells 
to  cancer patients (Hinrichs et al., 2009). Once in vivo, TH17-polarized CD8+ T cells might be 
converted to an IFN-producing phenotype, induced tumour regression and persisted in the 
host longer than non-polarized cells. tumourIL-17 deficient mice (IL-17A knockout  
(IL-17A -/-) have accelerated tumour growth and more lung metastasis than wild-type mice 
(Kryczek et al., 2009b, Martin-Orozco et al., 2009, Wei et al., 2010). Transgenic expression of 
human or murine IL-17 in tumour cells suppresses or slows tumour growth and increases 
tumour-specific cytotoxic responses (Hirahara et al., 2001, Benchetrit et al., 2002). However, 
contrasting results were shown by Wang et al., 2009 who have reported that transferred 
tumours of B16 and bladder carcinoma MC49 grew more slowly in IL-17-/- mice.  
In prostate cancer patients, a significant inverse correlation was seen between TH17 cell 
differentiation and tumour progression (Sfanos et al., 2008). In addition to these evidences, it 
is known that IL-17 released by TH17 cells promote dendritic cell maturation which might 
allow for better tumour antigen presentation and thereby leading to a stronger T cell 
response. Furthermore, direct mechanistic and functional evidence that TH17 cells mediate 
antitumour immunity by promoting dendritic cell trafficking to tumour-draining lymph 
nodes, and to the tumour itself has also been provided (Martin-Orozco et al., 2009). 
tumourtumourMore recently, CTLA4 (cytotoxic T lymphocyte antigen 4) blockade was 
shown to increase TH17 cells in patients with metastatic melanoma and IL-17 levels in 
tumour-associated ascites positively predicted patient survival (von Euw et al., 2009). To 
summarize the above data, there is strong evidence that TH17 cells can have protective roles 
in tumour immunity but the exact nature of TH17 cells in anti-tumour immunity remains to 
be explored. 
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8. Conclusions 
Rapid and large advances in understanding the development, regulation and function of 
these cells have been made since TH17 cells are originally identified as a third lineage of 
effector T helper cells in 2005. The study of TH17 cells has been one of the fast-moving and 
exciting subject areas in immunology. This has been particularly true in the context of a 
diverse group of immune-mediated chronic inflammatory diseases and autoimmunity, 
where the pathogenic role of TH17 cells has been well documented. With regards to 
cancer, TH17 cells are found to be present in the tumour microenvironment though not as 
a predominant T cell subset within the tumour. Based on the evidence provided by both 
human and clinical studies data, TH17 cells and TH17-associated cytokines/effector 
molecules have been shown to have both pro-tumorigenic and anti-tumorigenic functions. 
On one hand it seems that the pro-inflammatory TH17 cells might engineer the 
microenvironment around tumours, and contribute to the proliferation, migration and 
survival of cancer cells. On the other hand, it is possible that inflammatory cells and 
molecules play roles to initiate and maintain protective anti-tumour immunity as seen in 
the case of infectious diseases (Punj et al., 2003). The IL-17 dependent pro-tumorigenic or 
anti-tumorigenic activity might be due to inherent technical limitations for example 
source and dose of exogenous versus endogenous IL‑17, in each of the studies (Zou and 
Restifo 2010). Further, based on the results from recent murine model studies, employing 
TH17-polarized T cells for cancer therapy may appear to be to be a promising approach for 
translational research. It is also important to study futher the specific nature of 
inflammatory response and the tissue context, so that the positive or negative effects of 
TH17 cells on tumour immunopathology can be determined. Equally important to 
understand is i) how the effector functions of TH17cells are regulated?, ii) how do the 
regulators of TH17-cell differentiation work? iii), do TH17 play same role in different types 
and stages of cancer?, and iv) how Treg cells can be suppressed in chronic inflammatory or 
large tumour burdens to increase the TH17 cells and later activation and proliferation of 
cytotoxic T cells to clear tumour cells? The answers will, help in designing future novel 
therapeutic vaccine approaches; specifically targeting inflammatory TH17 cells for cancer 
therapy. 
9. Abbreviations 
CD  Cluster of Differentiation 
IL  Interleukin 
IFN  Interferon 
TNF  Tumour Necrosis Factor 
TGF  Tumour Growth Factor 
MMP  Matrix Metalloproteinase 
APC  Antigen Presenting Cells 
FoxP3  Forkhead Box P3 
MAPK  Mitogen-Activated Protein Kinases 
TRAF6  Tumour Necrosis Factor Receptor-Associated Factor-6 
TLR  Toll-like Receptors 
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